Modeling glioblastoma complexity with organoids for personalized treatments
Copyright © 2023 Elsevier Ltd. All rights reserved..
Glioblastoma (GBM) remains a fatal diagnosis despite the current standard of care of maximal surgical resection, radiation, and temozolomide (TMZ) therapy. One aspect that impedes drug development is the lack of an appropriate model representative of the complexity of patient tumors. Brain organoids derived from cell culture techniques provide a robust, easily manipulatable, and high-throughput model for GBM. In this review, we highlight recent progress in developing GBM organoids (GBOs) with a focus on generating the GBM microenvironment (i.e., stem cells, vasculature, and immune cells) recapitulating human disease. Finally, we also discuss the use of organoids as a screening tool in drug development for GBM.
| Medienart: |
E-Artikel |
|---|
| Erscheinungsjahr: |
2023 |
|---|---|
| Erschienen: |
2023 |
| Enthalten in: |
Zur Gesamtaufnahme - volume:29 |
|---|---|
| Enthalten in: |
Trends in molecular medicine - 29(2023), 4 vom: 02. Apr., Seite 282-296 |
| Sprache: |
Englisch |
|---|
| Beteiligte Personen: |
Pawlowski, Kristen D [VerfasserIn] |
|---|
| Links: |
|---|
| Themen: |
Brain organoids |
|---|
| Anmerkungen: |
Date Completed 20.03.2023 Date Revised 28.12.2023 published: Print-Electronic Citation Status MEDLINE |
|---|
| doi: |
10.1016/j.molmed.2023.01.002 |
|---|
| funding: |
|
|---|---|
| Förderinstitution / Projekttitel: |
|
| PPN (Katalog-ID): |
NLM353116114 |
|---|
| LEADER | 01000caa a22002652 4500 | ||
|---|---|---|---|
| 001 | NLM353116114 | ||
| 003 | DE-627 | ||
| 005 | 20231229124105.0 | ||
| 007 | cr uuu---uuuuu | ||
| 008 | 231226s2023 xx |||||o 00| ||eng c | ||
| 024 | 7 | |a 10.1016/j.molmed.2023.01.002 |2 doi | |
| 028 | 5 | 2 | |a pubmed24n1241.xml |
| 035 | |a (DE-627)NLM353116114 | ||
| 035 | |a (NLM)36805210 | ||
| 035 | |a (PII)S1471-4914(23)00016-3 | ||
| 040 | |a DE-627 |b ger |c DE-627 |e rakwb | ||
| 041 | |a eng | ||
| 100 | 1 | |a Pawlowski, Kristen D |e verfasserin |4 aut | |
| 245 | 1 | 0 | |a Modeling glioblastoma complexity with organoids for personalized treatments |
| 264 | 1 | |c 2023 | |
| 336 | |a Text |b txt |2 rdacontent | ||
| 337 | |a ƒaComputermedien |b c |2 rdamedia | ||
| 338 | |a ƒa Online-Ressource |b cr |2 rdacarrier | ||
| 500 | |a Date Completed 20.03.2023 | ||
| 500 | |a Date Revised 28.12.2023 | ||
| 500 | |a published: Print-Electronic | ||
| 500 | |a Citation Status MEDLINE | ||
| 520 | |a Copyright © 2023 Elsevier Ltd. All rights reserved. | ||
| 520 | |a Glioblastoma (GBM) remains a fatal diagnosis despite the current standard of care of maximal surgical resection, radiation, and temozolomide (TMZ) therapy. One aspect that impedes drug development is the lack of an appropriate model representative of the complexity of patient tumors. Brain organoids derived from cell culture techniques provide a robust, easily manipulatable, and high-throughput model for GBM. In this review, we highlight recent progress in developing GBM organoids (GBOs) with a focus on generating the GBM microenvironment (i.e., stem cells, vasculature, and immune cells) recapitulating human disease. Finally, we also discuss the use of organoids as a screening tool in drug development for GBM | ||
| 650 | 4 | |a Journal Article | |
| 650 | 4 | |a Review | |
| 650 | 4 | |a Research Support, N.I.H., Extramural | |
| 650 | 4 | |a Research Support, Non-U.S. Gov't | |
| 650 | 4 | |a brain organoids | |
| 650 | 4 | |a drug screening | |
| 650 | 4 | |a glioblastoma | |
| 650 | 4 | |a tumor microenvironment | |
| 650 | 7 | |a Temozolomide |2 NLM | |
| 650 | 7 | |a YF1K15M17Y |2 NLM | |
| 700 | 1 | |a Duffy, Joseph T |e verfasserin |4 aut | |
| 700 | 1 | |a Babak, Maria V |e verfasserin |4 aut | |
| 700 | 1 | |a Balyasnikova, Irina V |e verfasserin |4 aut | |
| 773 | 0 | 8 | |i Enthalten in |t Trends in molecular medicine |d 2001 |g 29(2023), 4 vom: 02. Apr., Seite 282-296 |w (DE-627)NLM111960800 |x 1471-499X |7 nnns |
| 773 | 1 | 8 | |g volume:29 |g year:2023 |g number:4 |g day:02 |g month:04 |g pages:282-296 |
| 856 | 4 | 0 | |u http://dx.doi.org/10.1016/j.molmed.2023.01.002 |3 Volltext |
| 912 | |a GBV_USEFLAG_A | ||
| 912 | |a GBV_NLM | ||
| 951 | |a AR | ||
| 952 | |d 29 |j 2023 |e 4 |b 02 |c 04 |h 282-296 | ||